Skip to content

Talk Bio

Actionable Insights Powered by AI

Subscribe
  • Privacy policy
  • Subscribe
  • Home
  • DATE

DATE

  • Amino Acid, Peptide, or Protein
  • Biologically Active Substance
  • DATE

Crinetics Reports Over $5M in Q4 2025 PALSONIFY Revenue with Strong Launch Metrics

1 day ago talkbio0Tagged Acromegaly, Crinetics, enrollment forms, methionine, PALSONIFY, prescribers, Q4 2025, Revenue

Crinetics; PALSONIFY; Palsonify; Q4 2025; revenue; $5M; acromegaly; enrollment forms; prescribers

Read More
  • Amino Acid, Peptide, or Protein
  • Body Space or Junction
  • DATE

Novo Nordisk Launches Wegovy Pill in the US with Broad Availability

1 day ago talkbio0Tagged Glucagon-Like Peptide 1, January 2026, Novo Nordisk, Oral cavity, U.S., Wegovy pill, Weight Loss

Novo Nordisk; Wegovy pill; US launch; January 2026; oral GLP-1; weight loss

Read More
  • DATE
  • ENTITY
  • Geographic Area

Biotech’s Groove is Back for 2026: XBI Surges Amid M&A Boom and Lower Rates

2 days ago talkbio0Tagged Bassas da India, Lower Rates, M&A, trends qualifier

biotech; XBI; M&A; lower rates; 2026 trends

Read More
  • DATE
  • ENTITY
  • Governmental or Regulatory Activity

FDA Policy Tracker: 2025 Was a Year of Change

5 days ago talkbio0Tagged 2025, Drug Approval, Food Safety, GRAS Reform, Improvements, Mental Recall, Trump administration, United States Food and Drug Administration

FDA; 2025; Trump Administration; Food Safety; FSMA 204; GRAS Reform; Drug Approvals; Recall Improvements

Read More
  • Activity
  • DATE
  • Disease or Syndrome

Gilead’s $35M Herpes Deal with Assembly Biosciences and Recent FDA Approvals

2 weeks ago talkbio0Tagged ABI-5366, Assembly (construction), Boehringer, Gilead, Herpes NOS, Herpes Simplex Infections, Roche (company), United States Food and Drug Administration

Gilead; Assembly Biosciences; herpes; HSV; ABI-1179; ABI-5366; FDA; Boehringer; Roche

Read More
  • DATE
  • Disease or Syndrome
  • ENTITY

Spotlight On: Five Key FDA Approvals of 2025

2 weeks ago talkbio0Tagged 2025, approvals, Drugs, Orphan, Infrequent, United States Food and Drug Administration

FDA approvals; 2025; orphan drugs; novel therapies; rare diseases

Read More
  • DATE
  • Disease or Syndrome
  • ENTITY

Breakthrough Real-World Evidence Powering Blood Cancer Research in 2025

2 weeks ago talkbio0Tagged Asymmetric Septal Hypertrophy, hematologic care, Hematologic Neoplasms, real-world evidence, Real-world Evidence, SOHO

RWE; blood cancer; real-world evidence; ASH 2025; SOHO 2025; hematologic care

Read More
  • DATE
  • Disease or Syndrome
  • ENTITY

Bayer’s Finerenone Approved in Japan for Chronic Heart Failure Treatment

2 weeks ago talkbio0Tagged Approved, Bayer, Chronic heart failure, FINEARTS-HF, finerenone, HFmrEF, HFpEF, Japan, Kerendia

Finerenone; Kerendia; Japan approval; chronic heart failure; HFmrEF; HFpEF; Bayer; FINEARTS-HF

Read More
  • DATE
  • ENTITY
  • Idea or Concept

Biopharma’s Winners and Losers of 2025 – Endpoints News recap

3 weeks ago talkbio0Tagged 2025, Biopharma, Endpoints, Kyle LaHucik, Losers, movers, News [Publication Type], Pharma, Post-Hoc Live, Review [Publication Type], winners

Endpoints News; winners and losers; 2025; biopharma; Post-Hoc Live; Kyle LaHucik; year in review; biotech; pharma; stock movers

Read More
  • DATE
  • Disease or Syndrome
  • ENTITY

No public results for “Take the Biopharma Sentiment Index” Q1 2026 yet

3 weeks ago talkbio0Tagged Attitude, Biological Science Disciplines, Biopharma, biopharma executives, Biopharma Sentiment Index, geopolitical risk, M&A activity, Q1 2026, Sentiment, Surveys

Biopharma Sentiment Index; Q1 2026; biopharma executives; life sciences sentiment; 2026 outlook; M&A activity; AI in biopharma; geopolitical risk; survey data

Read More

Posts pagination

1 2 … 26 Next

Organizations

Agencies amgen AstraZeneca boehringer ingelheim Centers for Disease Control and Prevention (U.S.) Congress (U.S. Legislature) court Drug Industry European Medicines Agency genentech Government Health care facility Johnson and Johnson Moderna Novavax Partnership Pfizer Pharmacy Benefit Manager Pharmacy facility Roche (company) sandoz sanofi squibb United States Federal Trade Commission United States Food and Drug Administration World Health Organization

Concepts & Ideas

Accelerated Accelerated Approval Access accessibility Approved aspects of adverse effects asset Bankruptcy Benefit Capacity Capital Changing Chinese Language Clearance Clinical Data Combined commercial Complete Compound Contract agreement Cost Effectiveness development aspects Discontinuation (procedure) Diversity Dosage drug price Drug Shortage earnings Economic Inflation Effectiveness Efficiency Expectations Failed Failure (biologic function) Financial cost Financial savings financing characteristics Funding Generalized Health Identifier Improvement Increased Infrequent Legal Legal patent Long-term Moderate (severity modifier) New Drug Application Overall Survival Paroxysmal perioperative Phase 2 Phase 3 Prices Pricing Programs - Publication Format Progression-Free Survival Projections and Predictions Recommendation regulatory Review [Publication Type] rights Risk Series Statistical Significance Study on Hold subcutaneous Submission Symptoms aspect Toxicity aspects trends qualifier Variant Weekly

Procedures

Advice Cancer Therapeutic Procedure Cell Therapy Clinical Research Clinical Trials Combined Modality Therapy Confirmatory Trial Detection Drug Discovery Evaluation Gene Modification gene therapy HIV prevention Immunotherapy Injection of therapeutic agent Medical Research activity patient safety Pharmaceutical Services Pharmacotherapy Phase 2 Clinical Trials Phase 3 Clinical Trials Precision Medicine Prescription procedure Reparative closure research Telemedicine Vaccination

Occupations

Artificial Intelligence biology (field) Biotechnology Drug Development Genetic Medicine Global Health Immunology medical technology Neurology speciality Neuroscience discipline public health medicine (field) Science Science of genetics Technology

Disorders

Achondroplasia Acute onset pain Adverse event Amyotrophic Lateral Sclerosis Angioedemas, Hereditary Asthma Attention deficit hyperactivity disorder Autoimmune Diseases Brain Neoplasms Burning Mouth Syndrome Cardiomyopathies Cardiovascular Diseases Chronic Kidney Diseases Chronic Obstructive Airway Disease Colorectal Carcinoma COVID19 (disease) Dental Plaque Dermatitis, Atopic Diabetes Diabetes Mellitus, Non-Insulin-Dependent Disease Progression Eczema Epilepsy Esophageal Neoplasms Fibrosis Heart failure Hematologic Neoplasms Hemophilia A Hemophilia B Hereditary Diseases Hypoparathyroidism IGA Glomerulonephritis Infantile Severe Myoclonic Epilepsy Inflammation Inflammatory Bowel Diseases Inflammatory disorder Kidney Diseases leukemia Liver and Intrahepatic Biliary Tract Carcinoma Liver diseases Lung diseases Lupus Nephritis Lymphoma, Follicular Malignant neoplasm of breast Malignant neoplasm of endometrium Malignant neoplasm of lung Malignant neoplasm of prostate Malignant neoplasm of stomach Malignant neoplasm of urinary bladder Malignant Neoplasms Malignant tumor of cervix melanoma Mental Depression Mental deterioration Metabolic Diseases Multiple Acyl Coenzyme A Dehydrogenase Deficiency Multiple Myeloma Multiple Sclerosis Muscular Dystrophy Muscular Dystrophy, Duchenne Nance-Horan syndrome Narcolepsy Neoplasms Nerve Degeneration nervous system disorder Neurodegenerative Disorders Non-Small Cell Lung Carcinoma Nonalcoholic Steatohepatitis Obesity Paroxysmal nocturnal hemoglobinuria Post-Traumatic Stress Disorder Primary Biliary Cholangitis Psoriasis Pulmonary arterial hypertension Pulmonary Hypertension Reduced Schizophrenia Seizures Severe (severity modifier) Small cell carcinoma of lung Solid Neoplasm Spinal Muscular Atrophy Ulcerative Colitis Urinary tract infection Weight Loss

Objects

Arrowhead Facility (object) Investments Labels (device)

Chemicals & Drugs

Agonist agonists Antibiotics Antibodies Antibodies, Bispecific Antibody-Drug Conjugates Antineoplastic Agents Biological Factors Biosimilars BTK Inhibitor Cancer Vaccines Caplyta Clesrovimab Clustered Regularly Interspaced Short Palindromic Repeats Donanemab Dosage Forms Dupixent durvalumab Enhertu Epidermal Growth Factor Receptor Glucagon-Like Peptide-1 Receptor Glucagon-Like Peptide 1 Humira Imfinzi Immunologic Adjuvants Immunostimulating conjugate (antigen) Inhibitor inhibitors Insulin Jemperli Keytruda Lenacapavir Lumateperone Microbicides Midomafetamine Monoclonal Antibodies Mounjaro Nitroglycerin/Sodium Citrate/Ethanol Solution obinutuzumab Ocaliva Opdivo Ozempic patritumab Pediatric brand name pembrolizumab Primary Endpoint Radiopharmaceuticals RNA RNA, Messenger RNA, Small Interfering Rybrevant semaglutide Stelara Tagrisso Tecentriq therapeutic autologous dendritic cells tirzepatide Tremfya Trodelvy Vaccines Wegovy Weight-Loss Agents Zantac

Activities & Behaviors

Acquisition (action) Administration occupational activities Advisory Committees Agreement authorization Automation business career CEO Collaboration competition Continuance of life Drug Approval Industry Leadership Machine Learning Manufacture Mediation Medicare National Security Optimization production Rating (action) Rejection (Psychology) Relations Sales - occupational activity Settlement and Resettlement Success Withdraw (activity)

Geographic Areas

California China Japan Market North Carolina Singapore United States

Phenomena

Emergency Situation Motor function (observable entity) Safety

Living Beings

Adult Child Consumer European (ethnic group) HIV Ira (eukaryote) manager Partner in relationship Pet Animal Plants Respiratory syncytial virus

Anatomy

Cardiovascular system Carvykti Cells Liver Neurosecretory Systems T-Lymphocyte

Physiology

Biological Markers cellular targeting Cessation of life Decision Gene Expression Growth Hearing Immune response Menopause mental health Mutation Practice Experience Response process RNA Interference

Genes & Molecular Sequences

CSHL1 gene K-ras Oncogene PDCD1 gene PREP gene TIGIT gene TYK2 gene
Copyright © TalkBio 2024 Proudly powered by WordPress | Theme: ogma-blog by Mystery Themes.
  • Privacy policy
  • Subscribe